98%
921
2 minutes
20
C-reactive protein (CRP), an innate immune mediator, is elevated in the circulation before symptoms in patients with preeclampsia, a severe hypertensive pregnancy disorder with high mortality and morbidity. However, the specific sources underlying increased CRP and the role of elevated CRP in preeclampsia are undefined. Here, we report that circulating CRP levels are significantly increased in a large cohort of normotensive pregnant individuals when compared with nulligravid women and is further increased in patients with preeclampsia. These findings led us to discover further that placental syncytiotrophoblasts are previously unrecognized cellular sources of CRP and underlie elevated CRP in normotensive pregnant women and the additional increase in patients with preeclampsia. Next, we demonstrated that injection of CRP induces preeclampsia features, including hypertension (157 mm Hg CRP treated versus 119 mm Hg control), proteinuria (35.0 mg/μg CRP treated versus 14.1 mg/μg control), kidney, and placental damage and increased levels of sFlt-1 in pregnant mice but not in nonpregnant mice. Our study implicates that phosphocholine transferase, a placental-specific enzyme post-translationally modifying neurokinin B, is essential for the pathogenic role of CRP in preeclampsia through activation of the neurokinin 3 receptor. Overall, our studies have provided significant new insight on the pathogenic role of CRP in preeclampsia and highlighted innovative therapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736731 | PMC |
http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.04439 | DOI Listing |
J Med Internet Res
September 2025
Faculty of Medicine, The University of Sydney, Sydney, Australia.
Background: Hypertensive disorders of pregnancy (HDP) affect up to 10% of pregnancies and can have adverse short and long-term implications for women and their babies. eHealth interventions include any health service or treatment delivered using the internet and related technology that aims to facilitate, capture, or exchange knowledge. eHealth interventions are increasingly used across many health care settings with improved outcomes.
View Article and Find Full Text PDFFront Physiol
August 2025
Department of Ultrasound, Deyang People's Hospital, Deyang, Sichuan, China.
Background: Antiphospholipid syndrome (APS) is a major immune-related disorder that leads to adverse pregnancy outcomes (APO), including recurrent miscarriage, placental abruption, preterm birth, and fetal growth restriction. Antiphospholipid antibodies (aPLs), particularly anticardiolipin antibodies (aCL), anti-β2-glycoprotein I antibodies (aβ2GP1), and lupus anticoagulant (LA), are considered key biomarkers for APS and are closely associated with adverse pregnancy outcomes. This is a prospective observational cohort study to use machine learning model to predict adverse pregnancy outcomes in APS patients using early pregnancy aPL levels and clinical features.
View Article and Find Full Text PDFAm J Reprod Immunol
September 2025
Department of Obstetrics and Gynecology, Second XiangYa Hospital of Central South University, Changsha, Hunan, China.
Problem: Preeclampsia (PE) is a leading cause of perinatal maternal and fetal mortality. Clinical and pathological studies suggest that placental and decidual cell dysfunction may contribute to this condition. However, the pathogenesis of PE remains poorly understood.
View Article and Find Full Text PDFInt J Gynaecol Obstet
September 2025
Department of Gynecology and Obstetrics, Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin Medical University General Hospital, Tianjin, China.
Objective: To evaluate whether plasma levels of placental extracellular vesicles (pcEVs), the EV-scavenging factor lactadherin, and prothrombotic markers predict fetal growth restriction (FGR) and/or fetal distress (FD) in established severe pre-eclampsia (sPE).
Methods: We recruited 80 sPE patients, 41 normal pregnancies, and 27 non-pregnant women. SPE patients were further dichotomized into event and non-event groups based on the occurrence of FGR/FD during a follow-up period of 77 days.
JAMA
September 2025
Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands.
Importance: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks.
Objective: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth.